Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 33.42 1.12% 0.37
PTLA closed up 1.12 percent on Tuesday, March 19, 2019, on 49 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical PTLA trend table...

Date Alert Name Type % Chg
Mar 19 Golden Cross Bullish 0.00%
Mar 19 Doji - Bearish? Reversal 0.00%
Mar 19 BB Squeeze Ended Range Expansion 0.00%
Mar 18 Bollinger Band Squeeze Range Contraction 1.12%
Mar 18 Outside Day Range Expansion 1.12%
Mar 15 Bollinger Band Squeeze Range Contraction 0.39%
Mar 15 NR7 Range Contraction 0.39%
Mar 15 NR7-2 Range Contraction 0.39%
Mar 15 BB Squeeze Started Range Contraction 0.39%
Mar 14 NR7 Range Contraction 1.46%

Older signals for PTLA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Clinical Medicine Surgery Inflammation Seattle Genetics Spinal Muscular Atrophy Biogen Inflammatory Disorders Thrombosis Astellas Pharma Anticoagulants Factor X Hematologic Disorders Portola Pharmaceuticals
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 45.6
52 Week Low 14.81
Average Volume 1,523,239
200-Day Moving Average 28.6054
50-Day Moving Average 28.7874
20-Day Moving Average 32.124
10-Day Moving Average 32.739
Average True Range 1.2518
ADX 43.73
+DI 28.5172
-DI 11.581
Chandelier Exit (Long, 3 ATRs ) 31.9546
Chandelier Exit (Short, 3 ATRs ) 32.8154
Upper Bollinger Band 34.798
Lower Bollinger Band 29.45
Percent B (%b) 0.74
BandWidth 16.647989
MACD Line 1.3478
MACD Signal Line 1.5021
MACD Histogram -0.1543
Fundamentals Value
Market Cap 1.92 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -7.35
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.64
Resistance 3 (R3) 34.65 34.25 34.44
Resistance 2 (R2) 34.25 33.94 34.25 34.37
Resistance 1 (R1) 33.83 33.75 34.04 33.83 34.30
Pivot Point 33.44 33.44 33.54 33.43 33.44
Support 1 (S1) 33.02 33.13 33.23 33.01 32.54
Support 2 (S2) 32.63 32.94 32.62 32.47
Support 3 (S3) 32.21 32.63 32.40
Support 4 (S4) 32.20